Cancer Research Cancer Epigenetics  Jordan
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplementary Data
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yu, K.
Right arrow Articles by Tan, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yu, K.
Right arrow Articles by Tan, P.
[Cancer Research 64, 2962-2968, May 1, 2004]
© 2004 American Association for Cancer Research


Advances in Brief

A Molecular Signature of the Nottingham Prognostic Index in Breast Cancer

Kun Yu1, Chee How Lee1, Puay Hoon Tan2, Ga Sze Hong1, Siew Bok Wee1, Chow Yin Wong1 and Patrick Tan1,3

1 National Cancer Center and 3 Defence Medical and Environmental Research Institute, Republic of Singapore, and 2 Department of Pathology, Republic of Singapore

The Nottingham prognostic index (NPI) is a widely used clinicopathological staging system for breast cancer prognostication. Using a step-wise classification approach where breast tumor expression profiles were first divided into general "molecular subtypes" [estrogen receptor (ER)+, ER–, ERBB2+], followed by an independent analysis of each subtype, we identified a 62-gene expression signature (NPI-ES) highly correlated to the NPI in ER+ tumors. The NPI-ES classified the majority of ER+ tumors into two distinct groups with high confidence and was significantly correlated to NPI status in two independent sets of ER+ tumors derived from different centers. The NPI-ES is comparable to the classical NPI in identifying patients likely to exhibit a poor clinical prognosis, as well as to a recently described "prognosis signature" for breast cancer. Our findings demonstrate how expression profiling can complement classical staging systems employing histopathological parameters scored over a continuous range of values.




This article has been cited by other articles:


Home page
aacredbookHome page
A. Vincent-Salomon and O. Delattre
Role of Genetic, Genomic, and Transcriptomic Factors
Am. Assoc. Cancer Res. Educ. Book, April 18, 2009; 2009(1): 97 - 103.
[Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
J. A. Foekens, A. M. Sieuwerts, M. Smid, M. P. Look, V. de Weerd, A. W. M. Boersma, J. G. M. Klijn, E. A. C. Wiemer, and J. W. M. Martens
Four miRNAs associated with aggressiveness of lymph node-negative, estrogen receptor-positive human breast cancer
PNAS, September 2, 2008; 105(35): 13021 - 13026.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
E. A. Rakha, M. E. El-Sayed, A. H.S. Lee, C. W. Elston, M. J. Grainge, Z. Hodi, R. W. Blamey, and I. O. Ellis
Prognostic Significance of Nottingham Histologic Grade in Invasive Breast Carcinoma
J. Clin. Oncol., July 1, 2008; 26(19): 3153 - 3158.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
B. K.T. Tan, L. K. Tan, K. Yu, P. H. Tan, M. Lee, L. H. Sii, C. Y. Wong, G. H. Ho, A. W.Y. Yeo, P. K.H. Chow, et al.
Clinical Validation of a Customized Multiple Signature Microarray for Breast Cancer
Clin. Cancer Res., January 15, 2008; 14(2): 461 - 469.
[Abstract] [Full Text] [PDF]


Home page
Brief BioinformHome page
J. C. Hsu, J. Chang, T. Wang, E. Steingrimsson, M. K. Magnusson, and K. Bergsteinsdottir
Statistically designing microarrays and microarray experiments to enhance sensitivity and specificity
Brief Bioinform, January 1, 2007; 8(1): 22 - 31.
[Abstract] [Full Text] [PDF]


Home page
GENES CELLSHome page
K. Hara, K. I. Nakayama, and K. Nakayama
Geminin is essential for the development of preimplantation mouse embryos
Genes Cells, November 1, 2006; 11(11): 1281 - 1293.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
K. Yu, K. Ganesan, L. D. Miller, and P. Tan
A modular analysis of breast cancer reveals a novel low-grade molecular signature in estrogen receptor-positive tumors.
Clin. Cancer Res., June 1, 2006; 12(11): 3288 - 3296.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
F. Ambrogi, E. Biganzoli, P. Querzoli, S. Ferretti, P. Boracchi, S. Alberti, E. Marubini, and I. Nenci
Molecular Subtyping of Breast Cancer from Traditional Tumor Marker Profiles Using Parallel Clustering Methods
Clin. Cancer Res., February 1, 2006; 12(3): 781 - 790.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
A. Aggarwal, D. Li Guo, Y. Hoshida, S. Tsan Yuen, K.-M. Chu, S. So, A. Boussioutas, X. Chen, D. Bowtell, H. Aburatani, et al.
Topological and Functional Discovery in a Gene Coexpression Meta-Network of Gastric Cancer
Cancer Res., January 1, 2006; 66(1): 232 - 241.
[Abstract] [Full Text] [PDF]


Home page
Clin Med ResHome page
D. Cross and J. K. Burmester
The Promise of Molecular Profiling for Cancer Identification and Treatment
Clin. Med. Res., August 1, 2004; 2(3): 147 - 150.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2004 by the American Association for Cancer Research.